IL119417A - Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease - Google Patents

Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease

Info

Publication number
IL119417A
IL119417A IL11941796A IL11941796A IL119417A IL 119417 A IL119417 A IL 119417A IL 11941796 A IL11941796 A IL 11941796A IL 11941796 A IL11941796 A IL 11941796A IL 119417 A IL119417 A IL 119417A
Authority
IL
Israel
Prior art keywords
levodopa
parkinson
disease
pharmaceutical composition
transdermal administration
Prior art date
Application number
IL11941796A
Other languages
English (en)
Other versions
IL119417A0 (en
Original Assignee
Moshe Kushnir
Eliahu Heldman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moshe Kushnir, Eliahu Heldman filed Critical Moshe Kushnir
Priority to IL11941796A priority Critical patent/IL119417A/xx
Publication of IL119417A0 publication Critical patent/IL119417A0/xx
Priority to PCT/IL1997/000327 priority patent/WO1998016208A1/en
Priority to CA002268455A priority patent/CA2268455C/en
Priority to JP51815198A priority patent/JP2002513389A/ja
Priority to EP97944077A priority patent/EP1011644A4/en
Priority to AU45702/97A priority patent/AU4570297A/en
Priority to US09/711,709 priority patent/US6746688B1/en
Priority to AU15537/02A priority patent/AU768154B2/en
Publication of IL119417A publication Critical patent/IL119417A/xx
Priority to JP2008207049A priority patent/JP2009001588A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
IL11941796A 1996-10-13 1996-10-13 Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease IL119417A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL11941796A IL119417A (en) 1996-10-13 1996-10-13 Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
PCT/IL1997/000327 WO1998016208A1 (en) 1996-10-13 1997-10-09 Methods and apparatus for treatment of parkinson's disease
CA002268455A CA2268455C (en) 1996-10-13 1997-10-09 Methods and apparatus for treatment of parkinson's disease
JP51815198A JP2002513389A (ja) 1996-10-13 1997-10-09 パーキンソン病を治療するための方法並びに装置
EP97944077A EP1011644A4 (en) 1996-10-13 1997-10-09 METHOD AND APPARATUS FOR THE TREATMENT OF PARKINSON'S DISEASE
AU45702/97A AU4570297A (en) 1996-10-13 1997-10-09 Methods and apparatus for treatment of parkinson's disease
US09/711,709 US6746688B1 (en) 1996-10-13 2000-11-13 Apparatus for the transdermal treatment of Parkinson's disease
AU15537/02A AU768154B2 (en) 1996-10-13 2002-02-11 Treatment of Parkinson's disease
JP2008207049A JP2009001588A (ja) 1996-10-13 2008-08-11 パーキンソン病を治療するための方法並びに装置

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11941796A IL119417A (en) 1996-10-13 1996-10-13 Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease

Publications (2)

Publication Number Publication Date
IL119417A0 IL119417A0 (en) 1997-01-10
IL119417A true IL119417A (en) 2003-02-12

Family

ID=11069375

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11941796A IL119417A (en) 1996-10-13 1996-10-13 Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease

Country Status (6)

Country Link
EP (1) EP1011644A4 (xx)
JP (2) JP2002513389A (xx)
AU (1) AU4570297A (xx)
CA (1) CA2268455C (xx)
IL (1) IL119417A (xx)
WO (1) WO1998016208A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
WO1999030702A1 (fr) * 1997-12-17 1999-06-24 Sekisui Chemical Co., Ltd. Preparation a base de levodopa absorbable par voie percutanee
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
JP4608187B2 (ja) * 2002-02-28 2011-01-05 リンテック株式会社 経皮吸収型製剤
US7858112B2 (en) 2002-02-28 2010-12-28 Lintec Corporation Percutaneous absorption system and percutaneous absorption method
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
AT500095B8 (de) * 2004-01-23 2007-02-15 Braun Werner Mag Transdermales abgabesystem
CA2647986C (en) * 2006-03-31 2014-07-08 Erasmus University Medical Center Rotterdam Compositions for tumor growth control
ES2776734T3 (es) * 2010-11-15 2020-07-31 Neuroderm Ltd Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
AU2011341316A1 (en) * 2010-12-10 2013-07-04 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
JP2018514516A (ja) * 2015-03-30 2018-06-07 ベルリレム ゲーエムベーハー 水溶性ｌ‐ドーパエステル
EP3075723B1 (en) * 2015-03-30 2017-05-24 Berlirem GmbH Highly soluble l-dopa glycerol esters
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
JPH04261119A (ja) * 1991-02-13 1992-09-17 Lintec Corp 経皮吸収型貼付剤
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease

Also Published As

Publication number Publication date
JP2009001588A (ja) 2009-01-08
IL119417A0 (en) 1997-01-10
AU4570297A (en) 1998-05-11
CA2268455C (en) 2007-05-15
EP1011644A4 (en) 2006-02-08
CA2268455A1 (en) 1998-04-23
JP2002513389A (ja) 2002-05-08
EP1011644A1 (en) 2000-06-28
WO1998016208A1 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
IL119417A (en) Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
IL117728A0 (en) Pharmaceutical compositions for transdermal administration
HUP0100737A3 (en) Use of phytosterol for preventing and delaying the onset of alzheimer's disease and phytosterol containing pharmaceutical compositions
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
HUP0004096A3 (en) Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
EP0331620A3 (en) Agent for the treatment of parkinson's disease
ZA984266B (en) Pharmaceutical composition and process of preparation
IL127146A0 (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
HUP9904027A3 (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
ZA9670B (en) Composition and methods for transdermal delivery of acid-lability drugs
HUP0004331A3 (en) Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease
EP0953359A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HUP9702293A3 (en) 4-thiazolidinone, rhodanine and 1,3-oxathiolan-5-one derivatives for the preparation of pharmaceutical compositions suitable for the treatment of multiple sclerosis
HRP20010919B1 (en) Diphosphate salt of a 4''-substituted-9-deoxo-9a-aza-homoerythromycin derivative and its pharmaceutical composition
AU1807592A (en) New combination preparation for treatment of parkinson's disease
ZA984832B (en) Pharmaceutical form for the administration of paclitaxel process for the preparation of a ready-to-use paclitaxel composition and use of this composition
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
AU7622798A (en) Application of thalidomide to the treatment of Parkinson's disease and Parkisonian syndromes
HU9800623D0 (en) Oral application of "(+)-o-demethyl-tramadol as analgesic active component
AU2137595A (en) Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis
GB9820489D0 (en) Compounds for improved treatment of parkinson's disease

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees